These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 8937965)

  • 61. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015).
    Pfaller MA; Shortridge D; Sader HS; Castanheira M; Flamm RK
    Int J Antimicrob Agents; 2018 Feb; 51(2):181-189. PubMed ID: 28993143
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Disk agar diffusion susceptibility testing with 30-micrograms ceftazidime disks: confirmation of interpretive breakpoints and quality control guidelines.
    Jones RN; Barry AL; Thornsberry C
    J Clin Microbiol; 1983 Jul; 18(1):211-4. PubMed ID: 6350348
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Evaluation of the E test for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from patients with long-term bladder catheterization.
    Di Bonaventura G; Ricci E; Della Loggia N; Catamo G; Piccolomini R
    J Clin Microbiol; 1998 Mar; 36(3):824-6. PubMed ID: 9508323
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Criteria for the assessment of susceptibility to ceftazidime using the disc diffusion procedure.
    Grimm H
    Infection; 1983; 11 Suppl 1():S35-8. PubMed ID: 6339416
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A multicenter survey of resistance in The Netherlands using the Etest.
    van Klingeren B; Stobberingh EE; MacLaren DM; Schmitz PI; Murmans M; Smeets T; Dessens M
    Diagn Microbiol Infect Dis; 1994 Jul; 19(3):151-6. PubMed ID: 7820994
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Comparison of the antibacterial effects of cefepime and ceftazidime against Escherichia coli in vitro and in vivo.
    Mattie H; Sekh BA; van Ogtrop ML; van Strijen E
    Antimicrob Agents Chemother; 1992 Nov; 36(11):2439-43. PubMed ID: 1489186
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Stability and antibacterial activity of cefepime during continuous infusion.
    Sprauten PF; Beringer PM; Louie SG; Synold TW; Gill MA
    Antimicrob Agents Chemother; 2003 Jun; 47(6):1991-4. PubMed ID: 12760882
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Determination of interpretive breakpoints for ceftazidime disc-diffusion susceptibility testing using single-strain regression analysis.
    Petersson AC; Kronvall G
    Acta Pathol Microbiol Immunol Scand B; 1985 Aug; 93(4):289-96. PubMed ID: 3901667
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Effect of serum from different patient populations on the serum bactericidal test.
    Kays MB; White RL; Friedrich LV
    J Antimicrob Chemother; 2001 Sep; 48(3):417-20. PubMed ID: 11533009
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Susceptibility testing with disc diffusion for new cephalosporins: pre-diffusion revisited.
    Frimodt-Møller N; Hvass E; Højbjerg T; Møller S; Mortensen I; Thomsen VF
    Acta Pathol Microbiol Immunol Scand B; 1986 Jun; 94(3):159-66. PubMed ID: 3090857
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Agar well diffusion assay testing of bacterial susceptibility to various antimicrobials in concentrations non-toxic for human cells in culture.
    Holder IA; Boyce ST
    Burns; 1994 Oct; 20(5):426-9. PubMed ID: 7999271
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Comment on: An update on cefepime and its future role in combination with novel β-lactamase inhibitors for MDR Enterobacterales and Pseudomonas aeruginosa.
    Nicolau DP; Bhagwat SS; Abdelraouf K
    J Antimicrob Chemother; 2021 Nov; 76(12):3326-3327. PubMed ID: 34179957
    [No Abstract]   [Full Text] [Related]  

  • 73. Preliminary interpretive criteria for the Haemophilus Test Medium method using 30 micrograms cefepime disks.
    Jones RN
    Eur J Clin Microbiol Infect Dis; 1992 Feb; 11(2):207-8. PubMed ID: 1396744
    [No Abstract]   [Full Text] [Related]  

  • 74. An update on cefepime and its future role in combination with novel β-lactamase inhibitors for MDR Enterobacterales and Pseudomonas aeruginosa--authors' response.
    Isler B; Harris P; Stewart AG; Paterson DL
    J Antimicrob Chemother; 2021 Nov; 76(12):3327-3328. PubMed ID: 34624086
    [No Abstract]   [Full Text] [Related]  

  • 75. Ceftazidime susceptibility testing--disc loading.
    Crosse R; Burt DG; Gardner MJ
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():217-9. PubMed ID: 19802987
    [No Abstract]   [Full Text] [Related]  

  • 76. In-vitro activity of cefepime against bacterial pathogens from hospitalized patients.
    Klugman KP; Saunders J; Khoosal M
    J Antimicrob Chemother; 1993 Jul; 32(1):164-6. PubMed ID: 8226408
    [No Abstract]   [Full Text] [Related]  

  • 77. In-vitro activities of cefepime and other beta-lactam antibiotics against clinical isolates from a Colombian teaching hospital.
    Mattar S; Sánchez L; Pérez D; Arango A; Parodi R; Muelle C
    J Antimicrob Chemother; 1998 Oct; 42(4):550-2. PubMed ID: 9818761
    [No Abstract]   [Full Text] [Related]  

  • 78. Ensuring robustness in the quality of antibiotic susceptibility test discs for four novel antibiotics.
    Ahirrao VK; Jadhav RA; Vaidya SN; Bhagwat SS; Yeole RD; Patel MV
    Biomed Chromatogr; 2022 Jun; 36(6):e5354. PubMed ID: 35141944
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Evaluation of ceftazidime concentration released in agar from an E test strip.
    Vaiani R; Arcelloni C; Comuzzi B; Gesu G; Bonato C; Paroni R
    Eur J Clin Microbiol Infect Dis; 2000 Jul; 19(7):551-4. PubMed ID: 10968329
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Development and in-house validation of a microbiological assay for determination of cefepime in injectable preparations.
    Souza MJ; Kulmann RR; Silva LM; Nogueira DR; Zimmermann ES; Schmidt CA
    J AOAC Int; 2006; 89(5):1367-72. PubMed ID: 17042189
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.